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after previously failed catheter ablation or those 
at high risk of catheter ablation failure.1
Novel catheter and thoracoscopic technolo‑
gies have significantly improved AF treatment 
outcomes; however, AF still remains a complex 
condition requiring a multifaceted and multi‑
disciplinary management as well as close co‑
operation between cardiac surgeons and elec‑
trophysiologists. In high ‑volume centers, Elec‑
tro Heart Teams should therefore be created to 
support advanced AF management. Similar so‑
lutions are observed in different areas of cardi‑
ology, for example, heart failure management 
and transcatheter procedures.
The Electro Heart Team concept was intro‑
duced following the 6th German Atrial Fibril‑
lation Network association and European Heart 
Rhythm Association Conference.
The roles of the Electro Heart Team are as fol‑
lows: 1) complex rhythm control therapy, for ex‑
ample, when catheter ablation fails to control 
symptomatic AF, when AF surgery is consid‑
ered, or in situations that impair rhythm con‑
trol therapy; 2) complex stroke prevention, for 
example, when anticoagulation is contraindi‑
cated, or when left atrial appendage exclusion, 
ligation, or clipping are required.4
This year, an Electro Heart Team was estab‑
lished at the Jagiellonian University Medical 
College and the John Paul II Hospital in Kraków 
and consists of an electrocardiologist, a cardi‑
ac surgeon, and a cardiologist. The goal of our 
high ‑volume AF treatment center is to help low‑
‑volume centers manage complex cases.
The Team is also the best platform for coop‑
eration between an electrocardiologist and car‑
diac surgeon, and allows the use of hybrid treat‑
ments as an effective form of managing AF re‑
currence.1 The Team will also limit persistent ab‑
lations performed by less experienced centers, 
which is safer for patients and more economical 
for the healthcare system. Another advantage 
of the Electro Heart Team is their potential for 
complex stroke prevention, due to the cardiac 
To the editor In August 2020, the new Eu‑
ropean Society of Cardiology / European As‑
sociation of Cardio ‑Thoracic Surgery guide‑
line on atrial fibrillation (AF) was published.1 
We, therefore, read with interest the study by 
Wojdyła ‑Hordyńska et al,2 published in the Oc‑
tober 2020 issue of Kardiologia Polska (Kardiol Pol, 
Polish Heart Journal), presenting trends in endo‑
cardial treatment of AF using data from 38 Pol‑
ish electrophysiology centers. A systematic in‑
crease in endocardial AF ablations using domi‑
nant cryoballoon ablation was observed in 69% 
of cases, followed by radiofrequency ablation 
(31%). Importantly, the first or second redo abla‑
tion was performed more often by radiofrequen‑
cy catheter ablation and in high ‑volume centers 
with over 100 AF ablations annually.
Currently, AF is an epidemic with a 2% to 4% 
prevalence with a large increases in disease bur‑
den expected in the future. It is therefore pleas‑
ing to hear that 88 centers can perform endocar‑
dial ablation in Poland. Of note, many centers 
only carry out cryoablation, while radiofrequen‑
cy is done more frequently in high ‑volume cen‑
ters, similarly to a redo procedure. Atrial fibril‑
lation catheter ablation is very effective in sinus 
rhythm maintenance and should be the first ‑line 
therapy for rhythm control after failure or intol‑
erance to anti ‑arrhythmic drugs. Despite sever‑
al endocardial procedures and different ablation 
techniques, sinus rhythm maintenance may still 
not be achieved.1 Randomized controlled trials 
on thoracoscopic ablation demonstrated signifi‑
cantly higher freedom from atrial tachyarrhyth‑
mia and less need for repeat ablations after tho‑
racoscopic ablation compared with AF catheter 
ablation for paroxysmal or persistent AF.3 An‑
other advantage of thoracoscopic procedures is 
the likelihood of a simultaneous epicardial left 
atrial appendage occlusion (LAAO) which reduc‑
es stroke risk; however, surgical approaches were 
associated with more complication rates and 
severity. Thus, it seems reasonable to consider 
thoracoscopic surgery preferentially in patients 
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opportunity for patients with coronary heart 
disease, valve diseases or recurrent arrhyth‑
mia after endocardial surgery. This applies in 
particular to patients undergoing cardiac sur‑
gery during repair or replacement of the mi‑
tral valve. In the latest guidelines conducted in 
collaboration with the European Association 
of Cardio ‑Thoracic Surgery, a new register of 
the Polish National Health Service was men‑
tioned, which documented the improvement in 
survival, when ablation is performed concomi‑
tant to mitral valve repair or exchange or coro‑
nary surgery procedures.2
For this reason, the guidelines also include 
indications for surgical interventions in specif‑
ic subgroups of patients with atrial fibrillation.
Ablation of atrial fibrillation during cardi‑
ac surgery should be considered, taking into 
account the benefits of reducing the burden of 
arrhythmia and risk factors for recurrence (AF 
duration, left atrium size, patient age, AF du‑
ration, left ventricle or renal dysfunction) and 
other cardiovascular factors.
1	  Hybrid and thoracoscopic procedures should 
be considered in symptomatic patients with an‑
tiarrhythmic drugs ‑refractory paroxysmal and 
persistent AF or with recurrent arrhythmia af‑
ter percutaneous ablation based on the joint de‑
cision of electrophysiologists and cardiac sur‑
geons (IIA), or with persistent and symptom‑
atic arrhythmias despite using at least one an‑
tiarrhythmic (IIB) drug.
2	 In a subgroup of patients who do not toler‑
ate any antiplatelet therapy, either an epicardi‑
al catheter approach or thoracoscopic clipping 
of the left atrium appendage may be an option.3
In the group of patients without structural 
damage of the heart who underwent stand ‑alone 
surgical ablation, the 7‑year recurrence rate was 
low and complication rate was high compared 
with catheter ablation (the FAST [Atrial Fibril‑
lation Catheter Ablation Versus Surgical Abla‑
tion Treatment] study with recurrence rate 56% 
vs 87%).4 Yet, minimally ‑invasive surgical abla‑
tion in persistent AF is related to more proce‑
dural complications, the incidence of adverse 
events rate is high, the hospitalization longer, 
and there are no data reflecting the quality of 
life. Surgical AF ablation concomitant to other 
cardiac surgery significantly increases the need 
for pacemaker implantation especially with right 
atrium procedures. There are still no positive 
studies on the quality of life after cardiac sur‑
gery, the impact on the incidence of strokes both 
in the case of surgical isolation alone and in 
the case of the injury closure. Therefore, antico‑
agulant therapy must be continued. The adverse 
events after surgical ablation appear more se‑
vere than in catheter ablation, hence, a patient‑
‑tailored therapy choice is needed. The optimal 
method is therefore the use of electrophysio‑
logical and cardiosurgical resources in a hybrid 
surgery department required for LAAO proce‑
dures by the National Health Fund.5 Hospitals 
without a cardiac surgery department cannot 
perform LAAO procedures, which is the case 
of most electrophysiology laboratories in Po‑
land. Lastly, the Electro Heart Team will relieve 
the daily duties of traditional Heart Team.
In our opinion, the Electro Heart Team will 
improve outcomes of patients with AF and 
should be established in institutions aspiring 
to be high ‑volume centers.
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Authors’ reply Worldwide, atrial fibrilla‑
tion (AF) is the most common sustained car‑
diac arrhythmia in adults. It is therefore a unit 
that poses a great challenge to health systems. 
A great number of studies has been carried out 
and much more research is still needed to un‑
derstand the mechanisms of development and 
effective treatments for AF. Currently, in Po‑
land, the dominant method of treatment of atri‑
al fibrillation is percutaneous endocardial abla‑
tion, which is a safe and effective.1 Yet, models 
predicting the risk of recurrence after the pro‑
cedure and new treatment techniques are con‑
sidered necessary. The possibilities of interspe‑
cialization cooperation in cardiology and cardio‑
surgery within heart teams have become a new 
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method in which minimally invasive epicardial 
ablation and percutaneous endocardial one are 
performed, increasing the efficiency of complete 
pulmonary veins isolation and obtaining a low 
rate of atrial arrhythmias recurrence.5 The idea 
of creating heart teams seems to be promising, 
especially in high ‑volume centers with cardio‑
vascular surgery departments; such consulta‑
tions should be reserved for complicated cases, 
that is, with valvular defects, coronary artery 
disease, and after percutaneous redo procedures.
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